DeHeng Assisted Haisen Pharm in Obtaining the Approval of SZSE for Main-Board Listing Transfer

2023-03-16

On March 13, 2023, the application of Zhejiang Haisen Pharmaceutical Co., Ltd. For the initial public offering and listing was deliberated and approved at the 8th meeting of the Listing Review Committee of the Shenzhen Stock Exchange in 2023. This was one of the first main-board listing transfer applications reviewed and approved by the China Securities Regulatory Commission after the implementation of the comprehensive registration system reform of IPO.

As the issuer's legal counsel, the DeHeng team, with lawyers Ni Haizhong, Huang Junfu and Lou Mohan of Hangzhou Office as signing lawyers, and with primary support of lawyer Huang Luhao and paralegals Liu Xingyu and Wang Zian, provided whole-process professional, efficient and high-quality legal services and won high praises from the client.